Clinical trial
A Phase II, Trial of Ixabepilone Plus Cetuximab as First Line Therapy for…
NCT00383149 · R-Pharm, Industry · Completed
Key facts
| NCT number | NCT00383149 |
|---|---|
| Title | A Phase II, Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer |
| Official title | A Phase II, Open Label Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer |
| Lead sponsor | R-Pharm, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic Pancreatic Cancer |
| Intervention type | Drug |
| Interventions | Ixabepilone, Cetuximab |
| Enrollment | 58 |
| Start date | Jan 1, 2007 |
| Primary completion | Jun 1, 2009 |
| Completion | Jun 1, 2009 |
| First posted | Oct 2, 2006 |
| Last update posted | Mar 10, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: